Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

NCT03368131 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Trastuzumab
DRUG: Capecitabine
DRUG: Oxaliplatin
RADIATION: Radiotherapy

Sponsor

Hebei Medical University